Phototoxic Reaction Induced by Pazopanib

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Multikinase inhibitors (MKIs) represent a significant advancement in targeted cancer therapy, offering improved survival rates for advanced-stage malignancies.
• Adverse reactions, particularly dermatological, are common with MKIs, with photosensitivity being a recognized side effect of some agents like sunitinib and vandetanib.

Observation:

• A patient with advanced-stage renal cell carcinoma developed a severe skin reaction after initiating pazopanib therapy.
• The observed reaction was characterized by symptoms consistent with phototoxicity, occurring upon sun exposure.

Findings:

• This case report details the first documented instance of a phototoxic drug reaction specifically induced by pazopanib.
• The findings highlight a previously unrecognized adverse effect of pazopanib, expanding the known spectrum of MKI-associated dermatopathies.

Implications:

• Clinicians should be aware of the potential for pazopanib to induce phototoxic reactions, even though it has not been previously reported.
• This discovery necessitates careful patient counseling regarding sun exposure and the potential for photosensitivity when prescribing pazopanib.
• Further research is warranted to elucidate the mechanisms underlying pazopanib-induced phototoxicity and to establish management guidelines.